[New treatments in osteoporosis].

Abstract

New intermittent regimens with bisphosphonates such as oral ibandronate, and maybe annual intra-venous zoledronate, will be useful additions to the treatment of post-menopausal osteoporosis. Strontium ranelate is a new molecule that both inhibits bone resorption and stimulates bone formation, with proven efficacy to reduce fracture incidence. Teriparatide (1-34 fragment of parathyroid hormone), using daily subcutaneous injections, has also proven its efficacy to decrease vertebral and peripheral fracture risk in postmenopausal osteoporotic women. In the next five years, new SERMs and inhibitors of RANK-ligand might be new treatment options.

• Authors: R Chapurlat, P D Delmas
• Journal: La Revue de medecine interne (Rev Med Interne) Vol. 25 Suppl 5 Pg. S573-9 (Dec 2004) ISSN: 0248-8663 [Print] France
• Vernacular Title: Nouveaux traitements de l'ostéoporose.
• PMID: 15841950 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Diphosphonates
• Organometallic Compounds
• Thiophenes
• strontium ranelate
• Teriparatide

Topics

• Aged
• Bone Remodeling
• Diphosphonates (therapeutic use)
• Female
• Fractures, Bone (prevention & control)
• Humans
• Injections, Subcutaneous
• Middle Aged
• Organometallic Compounds (therapeutic use)
• Osteoporosis (drug therapy)
• Postmenopause
• Risk Factors
• Teriparatide (therapeutic use)
• Thiophenes (therapeutic use)